Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers November 19, 2018
Pharmacy Choice - Pharmaceutical News - PCI Synthesis Identifies Trends Affecting the Generic Drugs Sector in 2018 - November 19, 2018

Pharmacy News Article

 12/18/17 - PCI Synthesis Identifies Trends Affecting the Generic Drugs Sector in 2018

NEWBURYPORT, Mass., Dec. 18, 2017 (GLOBE NEWSWIRE) PCI Synthesis, Inc. (www.pcisynthesis.com), a pharmaceutical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products, issued its annual list of trends that will affect the emerging biotech and generic drug sectors, as well as Contract Development and Manufacturing Organizations (CDMOs), Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) in 2018.

Were expecting a wave of innovation to drive the sector, said Ed Price, president of PCI Synthesis. When we looked at it, the one thing most of our trends this year have in common, it's innovation, whether it's the demand for medical-grade polymers that allow for new delivery systems to make medicine more effective or pharma foods that need GMP manufacturing while offering patients new ways to treat chronic diseases. Next year should be a good one in terms of driving change in how we develop new drugs and therapies.

Here are some of the trends that PCI Synthesis expects will impact the industry next year:

  1. Keeping talented employees will be an important advantage, given an upcoming labor shortage. In Massachusetts alone, the industry is projected to need to fill 11,600 new jobs by 2022, with manufacturing jobs seeing a 32% increase over 2016's level, according to MassBioEd. While Massachusetts and some industry associations are promoting STEM majors, that's not enough to ensure there are enough skilled people necessary to fill those new jobs. Recruiting and training quality employees will be important but maintaining talented employees will be a key competitive advantage.
  2. Demand for medical-grade polymers heats up. From novel drug delivery systems to new materials in ophthalmic applications, medical-grade polymers are being used in a range of different applications. We expect demand to continue to grow with more experience and new science continuing to push out the frontiers of what's possible.
  3. Digital drugs may be the latest thing in branded pharma but wont take off in generic form. The FDA approved an antipsychotic pill that lets doctors track whether patients are taking their meds, as a way to ensure patient compliance, which sounds great. But dont count on seeing generic versions anytime soon. The reason: slim margins on generics preclude the extra costs of adding a tiny chip inside a pill.
  4. GMP manufacturing isnt just for drug discovery. The value of incorporating Good Manufacturing Practices (GMP) manufacturing is increasingly sought by pharma foods. In contrast to unregulated nutraceuticals, pharma foods include a pharmacological additive to improve health, and undergo clinical testing and must meet FDA guidelines which is why companies need GMP. Some expect this to be the next frontier.
  5. M&A will continue to be strong in 2018. Based on a strong market and the perception of a deal-friendly DOJ, we expect to see more deals in 2018, many focused at combining complementary resources. These new companies will need to be more efficient, and the people and expertise are part of the deal.
  6. The FDA wont roll back regulations. We dont see much change within the FDA in 2018 because we havent seen much in 2017. Unlike some other federal agencies, the FDA is still behaving as it always has, and we dont expect a significant rollback of regulations.

About PCI Synthesis
PCI Synthesis is a Pharmaceutical Development CMO (Contract Manufacturing Organization) based in Newburyport, MA and is the largest small molecule drug substance manufacturer in the New England area. PCI is also a commercial manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products for the medical device industry. As a contract manufacturing organization (CMO), PCI provides emerging and mid-sized pharmaceutical companies access to the expertise needed to develop and manufacture complex small molecules. To learn more about PCI Synthesis, its proprietary NCE development activities and process R&D capabilities please visit www.pcisynthesis.com.

Contact:
Linda Pendergast-Savage
Birnbach Communications
508-224-7905
lpendergastsavage@birnbachcom.com

Primary Logo

Source: PCI Synthesis


2017 GlobeNewswire, Inc.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Nov 19: ADHD in Children & Adults: Etiology, Pathology, Pharmacotherapy
Last Chance
Nov 20: Acne Vulgaris: Comprehensive Pharmaceutical Care
Nov 26: COPD Update for Pharmacy Professionals
Nov 27: Management of Bipolar Disorder
Nov 28: A Primer to Paleo
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415